Source: Fox News
Summary
The Centers for Disease Control and Prevention (CDC) has reported a significant increase in drug-resistant Shigella infections in the US between 2011 and 2023. Shigella is a gram-negative bacteria that causes a diarrheal illness called shigellosis. According to the CDC, 8.5% of Shigella infections in 2023 were highly drug-resistant, with no FDA-approved oral antimicrobial agents available to treat them. The majority of patients were adult men, and many required hospitalization.
Our Reading
The advice sounds familiar. The CDC’s warning about the rise of drug-resistant Shigella infections is a reminder that bacterial infections can evolve and adapt quickly. The fact that there are no FDA-approved oral antimicrobial agents available to treat drug-resistant Shigella cases is a concern. The CDC’s emphasis on ongoing surveillance and public health response is a familiar refrain. The recommendation to carefully wash hands with soap and water after activities that could cause exposure is a familiar piece of advice.
As we’ve seen before, the rise of drug-resistant infections is a complex issue that requires a multifaceted approach. The CDC’s findings highlight the need for continued research and development of new treatments.
The fact that Shigella germs can spread easily through an infected person’s stool and contaminated surfaces is a reminder of the importance of good hygiene practices. The CDC’s guidance on reducing the risk of contracting Shigella is a familiar set of recommendations.
It’s worth noting that the rise of drug-resistant infections is a global issue, and the CDC’s findings are likely to be of interest to public health officials around the world.
As we’ve seen before, the battle against bacterial infections is an ongoing one, and it requires continued vigilance and cooperation from public health officials, researchers, and the general public.
Author: Evan Null
